Baseline characteristics of study subjects
| Subjects n | 56 |
| Male | 36 (64.3) |
| Caucasian | 49 (87.5) |
| Age at initiation of infliximab therapy years | 48.7±10.1 |
| Disease duration at initiation of infliximab therapy years | 6.8±7.1 |
| Diagnosis of sarcoidosis | |
| Biopsy | 52 (92.9) |
| Bronchoalveolar lavage | 3 (5.4) |
| Clinical | 1 (1.8) |
| Smoking status | |
| Never-smokers | 27 (48.2) |
| Current smokers | 4 (7.1) |
| Former smokers | 25 (44.6) |
| Scadding stage | |
| 0 | 5 (8.9) |
| I | 6 (10.7) |
| II | 16 (28.6) |
| III | 14 (25.0) |
| IV | 15 (26.8) |
| Main treatment indication | |
| Pulmonary | 34 (60.7) |
| Cardiac | 2 (3.6) |
| Small fibre neuropathy | 8 (14.3) |
| Cutaneous | 4 (7.2) |
| Central nervous system | 3 (5.4) |
| Sinus | 1 (1.8) |
| Myositis | 1 (1.8) |
| Vocal cord paralysis | 1 (1.8) |
| Ossal | 1 (1.8) |
| Hypercalcaemia | 1 (1.8) |
| Tertiary referral | 52 (92.9) |
| Medication use prior to initiation of infliximab | |
| Corticosteroids | 54 (96.4) |
| Methotrexate | 51 (91.1) |
| Azathioprine | 6 (10.7) |
| Leflunomide | 1 (1.8) |
| Plaquenil | 8 (14.3) |
| Anti-TNF treatment | 13 (23.2) |
| None | 0 (0) |
| Use of ≥2 different drugs prior to infliximab | 52 (92.2) |
| Concomitant medication | |
| Corticosteroids | 24 (42.9) |
| Methotrexate | 46 (82.1) |
| Azathioprine | 4 (7.1) |
| Leflunomide | 1 (1.8) |
| None | 0 (0) |
| Pulmonary function parameters | |
| FVC L (% pred) | 3.32 (78.8) |
| FEV1 L (% pred) | 2.30 (66.8) |
| DLCOc L (% pred) | 6.01 (59.8) |
| 6MWD m (% pred) | 460.4 (62.2) |
| Measurements of disease activity and severity | |
| SUVmax lung parenchyma | 6.6±5.3 |
| SUVmax mediastinum | 5.7±3.2 |
| SUVmax total (including index localisation) | 9.0±5.2 |
| ACE U·L-1 | 89.73±49.7 |
| ACE Z-score | 4.26±4.8 |
| sIL-2R pg·mL-1 | 8824±8503 |
Data are presented as n (%) or mean±sd, unless otherwise stated. TNF: tumour necrosis factor; FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s; DLCOc: diffusing capacity for carbon monoxide corrected for haemoglobin; 6MWD: 6-min walking distance; SUVmax: maximum standardised uptake value on 18F-fluorodeoxyglucose by positron emission tomography; ACE: angiotensin-converting enzyme; sIL-2R: soluble interleukin-2 receptor.